Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Lance R Thomas"'
Autor:
Tessa M Popay, Jing Wang, Clare M Adams, Gregory Caleb Howard, Simona G Codreanu, Stacy D Sherrod, John A McLean, Lance R Thomas, Shelly L Lorey, Yuichi J Machida, April M Weissmiller, Christine M Eischen, Qi Liu, William P Tansey
Publikováno v:
eLife, Vol 10 (2021)
The oncoprotein transcription factor MYC is a major driver of malignancy and a highly validated but challenging target for the development of anticancer therapies. Novel strategies to inhibit MYC may come from understanding the co-factors it uses to
Externí odkaz:
https://doaj.org/article/858ae447047d4222bb272f96fbb33a0c
Autor:
Andrew J. Siladi, Jing Wang, Andrea C. Florian, Lance R. Thomas, Joy H. Creighton, Brittany K. Matlock, David K. Flaherty, Shelly L. Lorey, Gregory C. Howard, Stephen W. Fesik, April M. Weissmiller, Qi Liu, William P. Tansey
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-11 (2022)
Abstract WDR5 nucleates the assembly of histone-modifying complexes and acts outside this context in a range of chromatin-centric processes. WDR5 is also a prominent target for pharmacological inhibition in cancer. Small-molecule degraders of WDR5 ha
Externí odkaz:
https://doaj.org/article/4970649d70db445fb70eaa8e823937b6
Publikováno v:
Molecular & Cellular Oncology, Vol 7, Iss 2 (2020)
The oncoprotein transcription factor MYC is overexpressed in most cancers and is responsible for hundreds of thousands of cancer deaths worldwide every year. MYC is also a highly validated – but currently undruggable – anti-cancer target. We rece
Externí odkaz:
https://doaj.org/article/2a2e594b9e5d48a3bc01fda6686bdc6c
Autor:
Bojana Jovanović, Quanhu Sheng, Robert S. Seitz, Kasey D. Lawrence, Stephan W. Morris, Lance R. Thomas, David R. Hout, Brock L. Schweitzer, Yan Guo, Jennifer A. Pietenpol, Brian D. Lehmann
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-14 (2017)
Abstract Background Triple negative breast cancer (TNBC) is a heterogeneous disease that lacks unifying molecular alterations that can guide therapy decisions. We previously identified distinct molecular subtypes of TNBC (TNBCtype) using gene express
Externí odkaz:
https://doaj.org/article/0dd8174f05f648f7b930cfdb70942ede
Autor:
Erin R. Aho, Jing Wang, Rocco D. Gogliotti, Gregory C. Howard, Jason Phan, Pankaj Acharya, Jonathan D. Macdonald, Ken Cheng, Shelly L. Lorey, Bin Lu, Sabine Wenzel, Audra M. Foshage, Joseph Alvarado, Feng Wang, J. Grace Shaw, Bin Zhao, April M. Weissmiller, Lance R. Thomas, Christopher R. Vakoc, Matthew D. Hall, Scott W. Hiebert, Qi Liu, Shaun R. Stauffer, Stephen W. Fesik, William P. Tansey
Publikováno v:
Cell Reports, Vol 26, Iss 11, Pp 2916-2928.e13 (2019)
Summary: The chromatin-associated protein WDR5 is a promising target for pharmacological inhibition in cancer. Drug discovery efforts center on the blockade of the “WIN site” of WDR5, a well-defined pocket that is amenable to small molecule inhib
Externí odkaz:
https://doaj.org/article/624392b24e9c465daac627e90b1195e5
Autor:
William G. Payne, Caden Schlund, Feng Wang, Joy Creighton, William P. Tansey, Jonathan David Macdonald, Edward T. Olejniczak, Jason Phan, Alex G. Waterson, Shaun R. Stauffer, Bin Zhao, J. Grace Shaw, Selena Chacón Simon, Lance R. Thomas, Stephen W. Fesik
Publikováno v:
Journal of Medicinal Chemistry. 63:4315-4333
The frequent deregulation of MYC and its elevated expression via multiple mechanisms drives cells to a tumorigenic state. Indeed, MYC is overexpressed in up to ∼50% of human cancers and is considered a highly validated anticancer target. Recently,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a6c1574b1428b87d841f82960edb49e
https://doi.org/10.1021/acs.jmedchem.0c00224
https://doi.org/10.1021/acs.jmedchem.0c00224
Autor:
Jianhua Tian, Kevin B. Teuscher, Erin R. Aho, Joseph R. Alvarado, Jonathan J. Mills, Kenneth M. Meyers, Rocco D. Gogliotti, Changho Han, Jonathan D. Macdonald, Jiqing Sai, J. Grace Shaw, John L. Sensintaffar, Bin Zhao, Tyson A. Rietz, Lance R. Thomas, William G. Payne, William J. Moore, Gordon M. Stott, Jumpei Kondo, Masahiro Inoue, Robert J. Coffey, William P. Tansey, Shaun R. Stauffer, Taekyu Lee, Stephen W. Fesik
Publikováno v:
Journal of Medicinal Chemistry. 63:656-675
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::40dc8f49d750829b0bd7b963329455df
https://doi.org/10.1021/acs.jmedchem.9b01608
https://doi.org/10.1021/acs.jmedchem.9b01608
Autor:
Andrew J. Siladi, Jing Wang, Andrea C. Florian, Lance R. Thomas, Joy H. Creighton, Brittany K. Matlock, David K. Flaherty, Shelly L. Lorey, Gregory C. Howard, Stephen W. Fesik, April M. Weissmiller, Qi Liu, William P. Tansey
Publikováno v:
Scientific Reports
Scientific Reports, Vol 12, Iss 1, Pp 1-11 (2022)
Scientific Reports, Vol 12, Iss 1, Pp 1-11 (2022)
WDR5 nucleates the assembly of histone-modifying complexes and acts outside this context in a range of chromatin-centric processes. WDR5 is also a prominent target for pharmacological inhibition in cancer. Small-molecule degraders of WDR5 have been d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd72ecac5f8c74991ee8dce4e5b78a0d
https://pubmed.ncbi.nlm.nih.gov/35115608
https://pubmed.ncbi.nlm.nih.gov/35115608
Autor:
Clare M. Adams, William P. Tansey, Joy Creighton, April M. Weissmiller, Qi Liu, Stephen W. Fesik, Lance R. Thomas, Christine M. Eischen, Shelly L. Lorey, Jing Wang
Publikováno v:
Proceedings of the National Academy of Sciences of the United States of America
Significance The oncoprotein transcription factor MYC is a validated but challenging anticancer target. In this work, we show that WDR5—a well-structured protein with druggable pockets—could be a focal point for effective anti-MYC therapies. We d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::043eae7e8b7ba6cc85f3eb85236dccbc
http://europepmc.org/articles/PMC6911241
http://europepmc.org/articles/PMC6911241
Autor:
Jing Wang, April M. Weissmiller, Stacy D. Sherrod, Tessa M. Popay, Simona G. Codreanu, Qi Liu, Lance R. Thomas, John A. McLean, Clare M. Adams, William P. Tansey, Gregory C. Howard, Christine M. Eischen, Shelly L. Lorey, Yuichi J. Machida
Publikováno v:
eLife, Vol 10 (2021)
eLife
eLife
The oncoprotein transcription factor MYC is a major driver of malignancy and a highly validated but challenging target for the development of anticancer therapies. Novel strategies to inhibit MYC may come from understanding the co-factors it uses to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::934203009b3bc42bf5b991f8353ac55f
https://elifesciences.org/articles/60191
https://elifesciences.org/articles/60191